Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
7,397 ^JPY	-0.23%		+0.31%	+8.81%

Apr. 30	Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	CI
Apr. 19	Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30	CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	Apr. 25	CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	Apr. 19	MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	Apr. 18	CI
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	Mar. 28	CI
Final dividend	Mar. 27	FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	Mar. 21	CI
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06	MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05	AN
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 05	CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	Mar. 04	RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)	Mar. 04	RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	Mar. 04	RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings	Mar. 04	RE
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	Feb. 27	AN
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan	Feb. 27	CI
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	Feb. 26	DJ
Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open	Feb. 09	CI
Shionogi Buys Back Over 8 Billion Yen Worth of Shares in January	Feb. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Highlights

Filters